A series of personal injury suits filed in Los Angeles earlier this month alleges that a charity established by the financier Michael Milken, in conjunction with prostate cancer researchers nationwide, engaged in systematic promotion of PC-Spes, a “nutraceutical” that was sold as a mixture of Chinese herbs, but was laced with prescription drugs.
Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years.
NCI director creates four new deputy director positions to manage the Institute.
Five NCAB members complete terms.
Breast surgeon and advocate Susan Love weds surgeon Helen Cooksey in San Francisco.
Funding opportunities listed.
NIH Director Zerhouni to discuss Roadmap initiatives Feb. 27.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help